Adaptive Radiotherapy for Genitourinary Cancers
Prospective Study of siMultaneous Adaptive RadioTherapy for Local Boost for Prostate and Bladder Cancers (SMART-B01)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
60 participants
Dec 1, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are: Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy? Participants will: Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion
Eligibility
Inclusion Criteria6
- Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;
- Age ≥ 18 years;
- ECOG performance status score 0-2;
- No prior radiotherapy history within the current radiation field;
- No contraindications for MRI scanning;
- No contraindications for radiotherapy.
Exclusion Criteria2
- Patients with contraindications to radiotherapy;
- Patients unable to tolerate MRI or with contraindications to MRI scanning.
Interventions
Prostate cancer pts post-prostatectomy：95%PTVboost 7Gy/3.5Gy/2f，95%PTV 66Gy/2.0Gy/33f，w/o 95%PTVp 50Gy/2.0Gy/25f Bladder cancer pts with bladder-conserving txt：95%PGTV 18Gy/6.0Gy/3f，95%PTV 50Gy/2.0Gy/25f，w/o 95%PTVp 50Gy/2.0Gy/25f
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07324798